The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial

Ng, Vivian G.; Lansky, Alexandra J.; Meller, Stephanie; Witzenbichler, Bernhard; Guagliumi, Giulio; Peruga, Jan Z.; Brodie, Bruce R.; Shah, Ruchit; Mehran, Roxana; Stone, Gregg W.

doi:10.1177/2048872613507149

Cited by 89 publications

(67 citation statements)

References 42 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, the strongest predictor of POCE and TLF in our study was decreased cardiac systolic function, which is a traditional risk factor for increased mortality in AMI patients undergoing PCI [33,34]. This result was in contrast to that of the study by Park et al, in which chronic renal failure was the strongest predictor of TLF [17], and this discrepancy might be attributed to the difference in study populations between the two studies.…”

Section: Independent Predictors Of Stent-related Outcome and Patient-contrasting

confidence: 82%

Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction

Jeong

Ahn

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

Section: Independent Predictors Of Stent-related Outcome and Patient-contrasting

confidence: 82%

Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction

Jeong

Ahn

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

“…On the other hand, an impaired LV systolic function is an established marker of short and long‐term adverse clinical outcome after acute MI . In the recent HORIZON‐AMI trial, STEMI patients with impaired LVEF had significantly higher 1‐year MACE compared to patients with normal LV function even after adjustment for baseline characteristics . A high level of CEC does not necessarily indicate increased functional regenerative activity of these cells.…”

Section: Discussionmentioning

confidence: 98%

“…[28][29][30] In the recent HORIZON-AMI trial, STEMI patients with impaired LVEF had significantly higher 1-year MACE compared to patients with normal LV function even after adjustment for baseline characteristics. 31 A high level of CEC does not necessarily indicate increased functional regenerative activity of these cells. In vitro assays demonstrate that EPCs isolated from STEMI patients with high Killip score have lower angiogenic potential compared to patients with a low Killip score and normal control subjects.…”

Section: Discussionmentioning

confidence: 99%

Circulating Endothelial Cells and Endothelial Function Predict Major Adverse Cardiac Events and Early Adverse Left Ventricular Remodeling in Patients With ST‐Segment Elevation Myocardial Infarction

Hamid

Bakhoum

Sharaf

et al. 2016

J Interven Cardiology

View full text Add to dashboard Cite

Endothelial progenitor cells (EPCs) and circulating endothelial cells (CECs) are mobilized from the bone marrow and increase in the early phase after ST-elevation myocardial infarction (STEMI). The aim of this study was to assess the prognostic significance of CECs and indices of endothelial dysfunction in patients with STEMI. In 78 patients with acute STEMI, characterization of CD34+/VEGFR2+ CECs, and indices of endothelial damage/dysfunction such as brachial artery flow mediated dilatation (FMD) were determined. Blood samples for CECs assessment and quantification were obtained within 24 hours of admission and FMD was assessed during the index hospitalization. At 30 days follow up, the primary composite end point of major cardiac adverse events (MACE) consisting of all-cause mortality, recurrent non-fatal MI, or heart failure and the secondary endpoint of early adverse left ventricular (LV) remodeling were analyzed. The 17 patients (22%) who developed MACE had significantly higher CEC level (P = 0.004), vWF level (P =0.028), and significantly lower FMD (P = 0.006) compared to the remaining patients. Logistic regression analysis showed that CECs level and LV ejection fraction were independent predictors of MACE. The areas under the receiver operating characteristic curves (ROC) for CEC level, FMD, and the logistic model with both markers were 0.73, 0.75, and 0.82 respectively for prediction of the MACE. The 16 patients who developed the secondary endpoint had significantly higher CEC level compared to remaining patients (p =0.038). In conclusion, increased circulating endothelial cells and endothelial dysfunction predicted the occurrence of major adverse cardiac events and adverse cardiac remodeling in patients with STEMI.

show abstract

“…Despite the widespread adoption of mechanical reperfusion for acute myocardial infarction (AMI) and the use of optimal medical therapy, the medium‐to‐long term mortality remains as high as 7–12% . Impaired left ventricular ejection fraction (LVEF) following AMI is a powerful predictor of mortality as well as morbidity and increased risk of hospitalization for heart failure . These realities have fuelled the search for novel therapies to improve cardiac function following AMI.…”

Section: Introductionmentioning

confidence: 99%

The effect of intracoronary infusion of bone marrow‐derived mononuclear cells on all‐cause mortality in acute myocardial infarction: rationale and design of the BAMI trial

Mathur

Arnold

Aßmus

et al. 2017

European J of Heart Fail

View full text Add to dashboard Cite

Over the past 13 years bone marrow-derived mononuclear cells (BM-MNCs) have been widely investigated for clinical efficacy in patients following acute myocardial infarction (AMI). These early phase II trials have used various surrogate markers to judge efficacy and, although promising, the results have been inconsistent. The phase III BAMI trial has therefore been designed to demonstrate that intracoronary infusion of BM-MNCs is safe and will significantly reduce the time to first occurrence of all-cause death in patients with reduced left ventricular ejection fraction after successful reperfusion for ST-elevation AMI (powered with the aim of detecting a 25% reduction in all-cause mortality). This is a multinational, multicentre, randomized, open-label, controlled, parallel-group phase III study aiming to enrol approximately 3000 patients in 11 European countries with at least 17 sites. Eligible patients who have impaired left ventricular ejection (≤45%) following successful reperfusion for AMI will be randomized to treatment or control group in a 1:1 ratio. The treatment group will receive intracoronary infusion of BM-MNCs 2-8 days after successful reperfusion for AMI added on top of optimal standard of care. The control group will receive optimal standard of care. The primary endpoint is time from randomization to all-cause death. The BAMI trial is pivotal and the largest trial to date of BM-MNCs in patients with impaired left ventricular function following AMI. The aim of the trial is to provide a definitive answer as to whether BM-MNCs reduce all-cause mortality in this group of patients.

show abstract

The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial

Cited by 89 publications

References 42 publications

Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction

Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction

Circulating Endothelial Cells and Endothelial Function Predict Major Adverse Cardiac Events and Early Adverse Left Ventricular Remodeling in Patients With ST‐Segment Elevation Myocardial Infarction

The effect of intracoronary infusion of bone marrow‐derived mononuclear cells on all‐cause mortality in acute myocardial infarction: rationale and design of the BAMI trial

Contact Info

Product

Resources

About